Stay updated on Lenvatinib and Pembrolizumab in HCC Clinical Trial
Sign up to get notified when there's something new on the Lenvatinib and Pembrolizumab in HCC Clinical Trial page.

Latest updates to the Lenvatinib and Pembrolizumab in HCC Clinical Trial page
- CheckyesterdayChange DetectedThe page now shows a 403 Forbidden error, replacing the study record with a minimal error screen and navigation header.SummaryDifference18%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedAn NIH funding note '2018 ( U.S. NIH Grant/Contract )' was added and a new page revision tag 'Revision: v3.6.6' was introduced, while the 'Plain Language Summary' and the previous revision tag 'Revision: v3.6.5' were removed.SummaryDifference0.1%

- Check43 days agoChange DetectedThe page now shows Revision: v3.6.5, replacing the previous Revision: v3.6.4, indicating a new build of the site.SummaryDifference0.0%

- Check58 days agoChange DetectedRevision tag updated from v3.6.3 to v3.6.4, signaling a small page-level update. This change does not alter trial details or user-facing features.SummaryDifference0.0%

- Check79 days agoChange DetectedPage revision updated from v3.6.2 to v3.6.3, indicating a minor update to the page's template or metadata. This appears to be an internal version bump rather than a change to study content or user-facing information.SummaryDifference0.0%

- Check86 days agoChange DetectedThe page’s revision tag was updated from v3.6.0 to v3.6.2. This reflects a minor update to the page content rather than substantive changes to the study details.SummaryDifference0.0%

Stay in the know with updates to Lenvatinib and Pembrolizumab in HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenvatinib and Pembrolizumab in HCC Clinical Trial page.